These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 22547261)

  • 1. Therapy: Neuroendocrine cancer--are two radionuclides better than one?
    Kwekkeboom DJ
    Nat Rev Endocrinol; 2012 May; 8(6):326-8. PubMed ID: 22547261
    [No Abstract]   [Full Text] [Related]  

  • 2. Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues.
    Bodei L; Pepe G; Paganelli G
    Eur Rev Med Pharmacol Sci; 2010 Apr; 14(4):347-51. PubMed ID: 20496546
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-emitting radionuclides for peptide receptor radionuclide therapy.
    Parus JL; Mikolajczak R
    Curr Top Med Chem; 2012; 12(23):2686-93. PubMed ID: 23339764
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peptide receptor radionuclide therapy for neuroendocrine tumors in Germany: first results of a multi-institutional cancer registry.
    Hörsch D; Ezziddin S; Haug A; Gratz KF; Dunkelmann S; Krause BJ; Schümichen C; Bengel FM; Knapp WH; Bartenstein P; Biersack HJ; Plöckinger U; Schwartz-Fuchs S; Baum RP
    Recent Results Cancer Res; 2013; 194():457-65. PubMed ID: 22918775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives.
    Breeman WA; de Jong M; Kwekkeboom DJ; Valkema R; Bakker WH; Kooij PP; Visser TJ; Krenning EP
    Eur J Nucl Med; 2001 Sep; 28(9):1421-9. PubMed ID: 11585303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Peptide receptor radionuclide therapy of neuroendocrine tumors].
    Arveschoug AK; Hjorthaug K; Rehling M; Højgaard L; Mortensen J; Oturai PS
    Ugeskr Laeger; 2009 Mar; 171(13):1073. PubMed ID: 19321068
    [No Abstract]   [Full Text] [Related]  

  • 7. Targeted radiotherapy with radiolabeled somatostatin analogs.
    Nicolas G; Giovacchini G; Müller-Brand J; Forrer F
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):187-204, ix-x. PubMed ID: 21349419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular radiotherapy with somatostatin analogs for (neuro-)endocrine tumors.
    Krenning EP; Teunissen JJ; Valkema R; deHerder WW; deJong M; Kwekkeboom DJ
    J Endocrinol Invest; 2005; 28(11 Suppl International):146-50. PubMed ID: 16625865
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Somatostatin receptor-targeted radionuclide therapy in patients with gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; de Herder WW; Krenning EP
    Endocrinol Metab Clin North Am; 2011 Mar; 40(1):173-85, ix. PubMed ID: 21349418
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Somatostatin receptor endoradiotherapy of neuroendocrine tumors: experience in Hungarian patients].
    Reismann P; Kender Z; Dabasi G; Sréter L; Rácz K; Igaz P
    Orv Hetil; 2011 Mar; 152(10):392-7. PubMed ID: 21354955
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 68Gallium- and 90Yttrium-/ 177Lutetium: "theranostic twins" for diagnosis and treatment of NETs.
    Werner RA; Bluemel C; Allen-Auerbach MS; Higuchi T; Herrmann K
    Ann Nucl Med; 2015 Jan; 29(1):1-7. PubMed ID: 25139472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review.
    Stolniceanu CR; Nistor I; Bilha SC; Constantin V; Simona V; Matovic M; Stefanescu C; Covic A
    Nucl Med Commun; 2020 Jul; 41(7):601-617. PubMed ID: 32404645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prior Resection of the Primary Tumor Prolongs Survival After Peptide Receptor Radionuclide Therapy of Advanced Neuroendocrine Neoplasms.
    Kaemmerer D; Twrznik M; Kulkarni HR; Hörsch D; Sehner S; Baum RP; Hommann M;
    Ann Surg; 2021 Jul; 274(1):e45-e53. PubMed ID: 33030849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polish experience in Peptide receptor radionuclide therapy.
    Kunikowska J; Królicki L; Sowa-Staszczak A; Hubalewska-Dydejczyk A; Pawlak D; Mikolajczak R; Handkiewicz-Junak D; Szaluś N; Kamiński G; Cwikla J; Jakuciński M; Lukiewicz A; Kowalska A; Gut P
    Recent Results Cancer Res; 2013; 194():467-78. PubMed ID: 22918776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Repeated cycles of peptide receptor radionuclide therapy (PRRT)--results and side-effects of the radioisotope 90Y-DOTA TATE, 177Lu-DOTA TATE or 90Y/177Lu-DOTA TATE therapy in patients with disseminated NET.
    Pach D; Sowa-Staszczak A; Kunikowska J; Królicki L; Trofimiuk M; Stefańska A; Tomaszuk M; Głowa B; Mikołajczak R; Pawlak D; Jabrocka-Hybel A; Hubalewska-Dydejczyk AB
    Radiother Oncol; 2012 Jan; 102(1):45-50. PubMed ID: 21885142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors.
    Kwekkeboom DJ; Kam BL; van Essen M; Teunissen JJ; van Eijck CH; Valkema R; de Jong M; de Herder WW; Krenning EP
    Endocr Relat Cancer; 2010 Mar; 17(1):R53-73. PubMed ID: 19995807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lutetium-labelled peptides for therapy of neuroendocrine tumours.
    Kam BL; Teunissen JJ; Krenning EP; de Herder WW; Khan S; van Vliet EI; Kwekkeboom DJ
    Eur J Nucl Med Mol Imaging; 2012 Feb; 39 Suppl 1(Suppl 1):S103-12. PubMed ID: 22388631
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours.
    Forrer F; Mueller-Brand J; Maecke H
    Eur J Nucl Med Mol Imaging; 2005 Apr; 32(4):511-2; author reply 513. PubMed ID: 15688195
    [No Abstract]   [Full Text] [Related]  

  • 19. Peptide Receptor Radionuclide Therapy for Advanced Gastroenteropancreatic Neuroendocrine Tumors - from oncology perspective.
    Kolasińska-Ćwikła A; Łowczak A; Maciejkiewicz KM; Ćwikła JB
    Nucl Med Rev Cent East Eur; 2018; 21(2):. PubMed ID: 29741203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Yttrium-90-labelled somatostatin-analogue for cancer treatment.
    Otte A; Mueller-Brand J; Dellas S; Nitzsche EU; Herrmann R; Maecke HR
    Lancet; 1998 Feb; 351(9100):417-8. PubMed ID: 9482300
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.